XML 13 R25.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Related Party Transactions (Details Textual) (USD $) | 0 Months Ended | 1 Months Ended | 3 Months Ended |  |  | 0 Months Ended | 1 Months Ended | 9 Months Ended | 1 Months Ended | 9 Months Ended |  | 1 Months Ended | 0 Months Ended | 6 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |  | 0 Months Ended | 1 Months Ended | 9 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 07, 2014 | Mar. 24, 2014 | Apr. 28, 2014 | Sep. 30, 2014 | Jul. 10, 2014 | Jan. 10, 2014 Placement agent [Member] | Dec. 09, 2013 Placement agent [Member] | Aug. 07, 2012 Placement agent [Member] | Sep. 30, 2014 Placement agent [Member] | Dec. 27, 2013 Investors [Member] | Jan. 31, 2014 Common Stock [Member] | Sep. 30, 2014 Common Stock [Member] | Jan. 31, 2014 Common Stock [Member] Placement agent [Member] | Jan. 31, 2014 Warrant [Member] | Jul. 10, 2014 IPO [Member] | Jun. 30, 2014 IPO [Member] | Sep. 30, 2014 MSKCC [Member] | Sep. 30, 2013 MSKCC [Member] | Sep. 30, 2014 MSKCC [Member] | Sep. 30, 2013 MSKCC [Member] | Sep. 30, 2014 MSKCC [Member] Clinical Trial Agreement [Member] | Dec. 31, 2013 MSKCC [Member] Clinical Trial Agreement [Member] | Dec. 31, 2012 MSKCC [Member] Clinical Trial Agreement [Member] | Mar. 27, 2012 MSKCC [Member] Clinical Trial Agreement [Member] | Sep. 04, 2013 SKI [Member] License, Development and Commercialization Agreement [Member] | Jun. 19, 2011 SKI [Member] License, Development and Commercialization Agreement [Member] | Sep. 30, 2014 SKI [Member] License, Development and Commercialization Agreement [Member]
Related Party Transactions (Textual) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount paid under agreement in 2011 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 50,000 |
Amount paid under agreement in 2012 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 |
Amount paid under agreement in 2013 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 250,000 |
Amount owed under agreement from 2011 to 2014 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 815,100 |  |
Maintenance fees |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 26,000 | 0 | 197,106 | 218,604 | 278,291 | 81,185 |  |  |  | 50,000 | 189,000
Placement agent services fees |  |  |  |  |  |  |  |  | 400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants issued to purchase common stock, shares |  |  |  |  |  |  |  |  | 68,976 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common stock exercise price per share |  |  |  | $ 9.00 |  |  |  |  | $ 9 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Amount paid to each patient after Completing clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,185 |  |  |
Start-up fee for clinical trial |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 79,623 |  |  |  |
Description of receivables of placement agent for services |  |  |  |  |  |  | Agreement entered in on December 9, 2013 had similar terms as the 2012 agreement, including a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock | Placement agent received (a) a cash fee equal to 10% of the gross proceeds raised in the 2012 Common Stock Offering, (b) a non-accountable expense reimbursement equal to 2% of the gross proceeds raised in the 2012 Common Stock Offering, and (c) reimbursement of $100,000 for legal expenses incurred by the placement agent. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of warrants receivables by placement |  |  |  |  |  |  | Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable | The placement agent or its designees also received warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued as part of the units sold in the 2012 Common Stock Offering and the shares of Common Stock issuable upon exercise of the B warrants included in such units. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Period of exercise of warrants |  |  |  |  |  |  |  | Within 6 months of the final closing of the 2012 common stock Offering | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of solicitation fee |  |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Monthly fee for financial advisory services |  |  |  |  |  |  | 25,000 | 25,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Description of additional receivable by placement agent |  |  |  |  |  |  |  | The agreement also provides that (i) if the Company consummates any merger, acquisition, business combination or other transaction (other than the Share Exchange) with any party introduced to it by the placement agent, the placement agent would receive a fee equal to 10% of the aggregate consideration in such transactions, and (ii) if, within a period of 12 months after termination of the advisory services described above, the Company requires a financing or similar advisory transaction the placement agent will have the right to act as the Company's financial advisor and investment banker in such financing or transaction pursuant to a set fee schedule set forth in the August 7, 2012 engagement agreement. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant held by placement agent to purchase common stock |  |  |  |  |  |  |  | 1,251,015 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty description |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. |  |  |  |  |  |  |  |
Common stock sold, Shares | 61,538 |  | 500 |  |  |  |  |  |  | 554,310 | 551,810 | 1,984,524 |  |  | 1,827,123 | 1,670,000 |  |  |  |  |  |  |  |  |  |  |
Warrants granted |  |  |  |  |  |  |  |  |  |  |  |  |  | 137,952 |  |  |  |  |  |  |  |  |  |  |  |  |
Sale of Stock, Price Per Share |  |  |  |  | $ 7.50 |  |  |  |  | $ 6.00 | $ 6.00 |  |  | $ 9.00 |  | $ 7.50 |  |  |  |  |  |  |  |  |  |  |
Class of Warrant or Right, Exercise Price of Warrants or Rights |  |  |  |  |  |  |  |  |  |  |  |  | $ 6.00 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds from the sale of securities |  |  |  |  |  | 3,310,860 |  |  |  | 3,325,860 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Underwriting discount |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,700,000 | 876,750 |  |  |  |  |  |  |  |  |  |  |
Gross proceeds received in Offering |  |  |  |  |  | $ 6,636,720 |  |  |  |  |  |  |  |  | $ 12,600,000 | $ 11,451,250 |  |  |  |  |  |  |  |  |  |  |
Aggregate offering amount of securities sold to investors |  | The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV. |  |  |  | Aggregate offering amount of securities sold to investors was increased from $6,000,000 to $6,636,720 in order to cover over-allotments |  |  |  | Five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Amount to be paid for each Patient that has completed the clinical trial. + References No definition available. + Details
Name: | atnm_AmountPaidToEachPatient
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount paid under agreement in year two thousand eleven. + References No definition available. + Details
Name: | atnm_AmountPaidUnderAgreementInYearTwoThousandEleven
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount paid under agreement in year two thousand thirteen. + References No definition available. + Details
Name: | atnm_AmountPaidUnderAgreementInYearTwoThousandThirteen
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount paid under agreement in year two thousand twelve. + References No definition available. + Details
Name: | atnm_AmountPaidUnderAgreementInYearTwoThousandTwelve
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Common stock exercise price par or stated value per share. + References No definition available. + Details
Name: | atnm_CommonStockExercisePriceParOrStatedValuePerShare
Namespace Prefix: | atnm_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Common stock purchase by holding of warrant. + References No definition available. + Details
Name: | atnm_CommonStockPurchaseByHoldingOfWarrant
Namespace Prefix: | atnm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of additional receivable by placement agent. + References No definition available. + Details
Name: | atnm_DescriptionOfAdditionalReceivableByPlacementAgent
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of receivables of placement agent for services. + References No definition available. + Details
Name: | atnm_DescriptionOfReceivablesOfPlacementAgentForServices
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of warrants receivables by placement. + References No definition available. + Details
Name: | atnm_DescriptionOfWarrantsReceivablesByPlacement
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maintenance fees and research payments. + References No definition available. + Details
Name: | atnm_MaintenanceFeesAndResearchPayments
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Owed amount under agreement in year two thousand eleven to fourteen. + References No definition available. + Details
Name: | atnm_OwedAmountUnderAgreementInYearTwoThousandElevenToFourteen
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage of solicitation fee. + References No definition available. + Details
Name: | atnm_PercentageOfSolicitationFee
Namespace Prefix: | atnm_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Periodic fee for financial advisory services. + References No definition available. + Details
Name: | atnm_PeriodicFeeForFinancialAdvisoryServices
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period of exercise of warrants. + References No definition available. + Details
Name: | atnm_PeriodOfExerciseOfWarrants
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Placement agent services fees. + References No definition available. + Details
Name: | atnm_PlacementAgentServicesFees
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | atnm_RelatedPartyTransactionsTextualAbstract
Namespace Prefix: | atnm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Start-up fee for clinical trial. + References No definition available. + Details
Name: | atnm_StartUpFeeForClinicalTrial
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Underwriting discount. + References No definition available. + Details
Name: | atnm_UnderwritingDiscount
Namespace Prefix: | atnm_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Warrants Issued To Purchase Aggregate Shares Of Common Stock. + References No definition available. + Details
Name: | atnm_WarrantsIssuedToPurchaseCommonStock
Namespace Prefix: | atnm_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Description of the commitments made for future artist advances payable and royalty guarantees. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 440 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013 + Details
Name: | us-gaap_ArtistAdvancesAndRoyaltyGuaranteesCommitments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash inflow associated with the amount received from entity's first offering of stock to the public. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromIssuanceInitialPublicOffering
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26853-111562 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a),(b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569655-111683 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1B -URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4582445-111684 + Details
Name: | us-gaap_SaleOfStockDescriptionOfTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration